Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Biochem Funct ; 32(2): 164-76, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23836332

RESUMO

Glioblastomas (GBMs) are the most lethal primary brain tumours. Increasing evidence shows that brain tumours contain the population of stem cells, so-called cancer stem cells (CSCs). Stem cell marker CD133 was reported to identify CSC population in GBM. Further studies have indicated that CD133 negative cells exhibiting similar properties and are able to initiate the tumour, self-renew and undergo multilineage differentiation. GBM is a highly heterogeneous tumour and may contain different stem cell populations with different functional properties. We characterized five GBM cell lines, established from surgical samples, according to the marker expression, proliferation and differentiation potential. CD133 positive cell lines showed increased proliferation rate in neurosphere condition and marked differentiation potential towards neuronal lineages. Whereas two cell lines low-expressing CD133 marker showed mesenchymal properties in vitro, that is high proliferation rate in serum condition and differentiation in mesenchymal cell types. Further, we compared therapy resistance capacity of GBM cell lines treated with hydroxyurea. Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM. At least two different subtypes of GBM CSCs exist, which may have different biological characteristics and imply different therapeutic strategies.


Assuntos
Neoplasias Encefálicas/genética , Heterogeneidade Genética , Glioblastoma/genética , Células-Tronco Neoplásicas/fisiologia , Fenótipo , Antígeno AC133 , Adulto , Idoso , Antígenos CD/genética , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Neoplasias Encefálicas/patologia , Diferenciação Celular , Proliferação de Células , Resistencia a Medicamentos Antineoplásicos , Feminino , Glioblastoma/patologia , Glicoproteínas/genética , Humanos , Hidroxiureia/farmacologia , Masculino , Pessoa de Meia-Idade , Células-Tronco Neoplásicas/patologia , Peptídeos/genética , Células Tumorais Cultivadas
2.
Cell Biochem Funct ; 31(3): 214-27, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23001693

RESUMO

The capacity of cartilage self-regeneration is considered to be limited. Joint injuries often evolve in the development of chronic wounds on the cartilage surface. Such lesions are associated with articular cartilage degeneration and osteoarthritis. Re-establishing a correct micro/macro-environment into damaged joints could stop or prevent the degenerative processes. This study investigated the effect of polydeoxyribonucleotides (PDRNs) on cartilage degradation in vitro and on cartilage extracted cells. The activities of matrix metalloproteinases 2 and 9 were measured in PDRN-treated cells and in controls at days 0 and 30 of culture. Human nasal cartilage explants were cultured, and the degree of proteoglycan degradation was assessed by measuring the amount of glycosaminoglycans released into the culture medium. The PDRN properties compared with controls were tested on cartilage tissues to evaluate deposition of extracellular matrix. Chondrocytes treated with PDRNs showed a physiological deposition of extracellular matrix (aggrecan and type II collagen: Western blot, IFA, fluorescence activated cell sorting, Alcian blue and safranin O staining). PDRNs were able to inhibit proteoglycan degradation in cartilage explants. The activities of matrix metalloproteinases 2 and 9 were reduced in all PDRN-treated samples. Our results indicate that PDRNs are suitable for a long-term cultivation of in vitro cartilage and have therapeutic effects on chondrocytes by protecting cartilage.


Assuntos
Cartilagens Nasais/efeitos dos fármacos , Polidesoxirribonucleotídeos/farmacologia , Substâncias Protetoras/farmacologia , Adulto , Agrecanas/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Condrócitos/citologia , Condrócitos/metabolismo , Colágeno Tipo II/metabolismo , Matriz Extracelular/metabolismo , Humanos , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Cartilagens Nasais/citologia , Cartilagens Nasais/metabolismo
3.
Cell Biochem Funct ; 28(5): 343-51, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20535838

RESUMO

Glioblastoma Multiforme (GBM) is an incurable malignancy. GBM patients have a short life expectancy despite aggressive therapeutic approaches based on surgical resection followed by adjuvant radiotherapy and concomitant chemotherapy. Glioblastoma growth is characterized by a high motility of tumour cells, their resistance to both chemo/radio-therapy, apoptosis inhibition leading to failure of conventional therapy. Cancer Stem Cells (CSCs), identified in GBM as well as in many other cancer types, express the membrane antigen prominin-1 (namely CD133). These cells and normal Neural Stem Cells (NSC) share surface markers and properties, i.e. are able to self-renew and differentiate into multiple cell types. Stem cell self-renewal depends on microenvironmental cues, including Extracellular Matrix (ECM) composition and cell types. Therefore, the role of microenvironment needs to be evaluated to clarify its importance in tumour initiation and progression through CSCs. The specific microenvironment of CSCs was found to mimic in part the vascular niche of normal stem cells. The targeting of GMB CSCs may represent a powerful treatment approach. Lastly, in GBM patients cancer-initiating cells contribute to the profound immune suppression that in turn correlated with CSCs STAT3 (CD133 + ). Further studies of microenvironment are needed to better understand the origin of GMB/GBM CSCs and its immunosuppressive properties.


Assuntos
Glioblastoma/terapia , Células-Tronco Neoplásicas/metabolismo , Antígeno AC133 , Antígenos CD/metabolismo , Terapia Combinada , Resistencia a Medicamentos Antineoplásicos , Glioblastoma/imunologia , Glicoproteínas/metabolismo , Humanos , Células-Tronco Neoplásicas/citologia , Peptídeos/metabolismo
4.
J Radiol Case Rep ; 3(11): 33-40, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-22470629

RESUMO

A patient with neurological symptoms underwent CT scan that showed a sellar and suprasellar mass with bone erosions, involving especially the clivus and the right petrous apex. The first diagnostic hypothesis was chordoma in relation to the mass position. The MRI showed a solid well-enhancing mass; moreover another circumscribed lesion, with similar signal pattern, was found in the left mandibular condyle. the signal and the presence of another lesion did not agree with diagnosis of chordoma. FDG-PET/CT study showed multiple pathological uptakes suggesting a metastatic disease. A trans-sphenoidal excisional biopsy was performed and the histopathological analysis showed a population of cells consistent with a plasmacell tumor, confirmed by the presence of a monoclonal gammopathy on blood analysis. Our case suggests that FDG-PET/CT can modify the diagnostic and therapeutic procedures in myeloma, by evaluating the bone marrow involvement.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...